Fig. 2.

CAR T-cell therapy. T cells are collected from the patient and genetically modified to include antigen receptors that combine the single-chain variable fragment of an antibody with intracellular signaling domains. Thus, they can recognize tumor cells expressing a tumor-associated antigen using lentiviral-vector technology. Engineered CAR T cells are expanded in the laboratory and transfused back into the patient.